moomoo ID:NaN
Log Out
Log in to access Online Inquiry

The latest announcement of Lisheng Pharmaceutical: subsidiary cefdinir dispersible tablets pass consistency evaluation

證券之星 ·  {{timeTz}}


According to Lisheng Pharmaceutical announcement, Tianjin Central Pharmaceutical Co., Ltd., a subsidiary of the company, received a "Drug Supplementary Application approval" (batch number: 2021B03871) and a "Drug Supplementary Application approval" (batch number: 2021B03872) of 0.1g cefdinir dispersible tablets (hereinafter referred to as "the drug") issued by the State Drug Administration. The two specifications of the drug (0.1g X 50mg) passed the generic drug quality and efficacy consistency evaluation.


The third quarterly report of 2021 of Lisheng Pharmaceutical showed that the company's main income was 836 million yuan, down 8.71% from the same period last year; the net profit was 97.717 million yuan, up 23.43% from the same period last year; and the non-net profit was 94.4448 million yuan, up 20.12% from the same period last year. In the third quarter of 2021, the company's main income in a single quarter was 248 million yuan, down 17.66% from the same period last year; and the net profit in a single quarter was 36.4642 million yuan, up 61.33% from the same period last year. The non-net profit in a single quarter was 35.7928 million yuan, up 57.46% from the same period last year; the debt ratio was 13.78%, the investment income was 11.4886 million yuan, the financial expenses were-56.2005 million yuan, and the gross profit margin was 58.16%.


The stock has no agency rating in the last 90 days. In the past three months, the net outflow of financing was 30.844 million, and the financing balance decreased; the net inflow of securities was 0, and the balance of securities lending increased. According to the Securities Star valuation analysis tool, Lisheng Pharmaceutical (002393) has a 2-star rating, a good price rating of 2 stars, and a comprehensive valuation rating of 2 stars.


The chairman of the company is Xu Daoqing. Mr. Xu Daoqing: born in August 1962, Chinese nationality, no permanent residence abroad, on-the-job graduate degree, bachelor's degree, senior engineer. He has successively served as the project leader, director, deputy director, deputy sales minister, marketing minister and deputy general manager of the Research Institute of Tianjin Central Pharmaceutical Co., Ltd.; the factory director of Tianjin Zhongxin Pharmaceutical Co., Ltd. is also the deputy general manager of Tianjin Zhongxin Pharmaceutical Group Co., Ltd.; party committee secretary, deputy factory director of Tianjin Zhongxin Pharmaceutical Longshunrong Pharmaceutical Factory, general manager of Tianjin Xinfeng Pharmaceutical Co., Ltd. Deputy General Manager and Chief engineer of Tianjin Zhongxin Pharmaceutical Group; Director and Deputy General Manager of Tianjin Lisheng Pharmaceutical Co., Ltd.; Party General Branch Secretary, Director, Vice Chairman and General Manager of Tianjin Darentang Jingwanhong Pharmaceutical Co., Ltd. He is currently the party committee secretary, director and chairman of Tianjin Lisheng Pharmaceutical Co., Ltd., and the director and chairman of Tianjin Tianbian Pharmaceutical Co., Ltd.


This article is compiled by the Securities Star data Center according to the public data and does not constitute investment opinions or suggestions. If there are any questions in the article, please contact us.

This page is machine-translated. Moomoo tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.